Reliance on CMOs and CROs has allowed the flexibility to make Gilead a top 10 pharma firm, and the use of third-parties will remain part of its strategy according to the CFO.
Neurologically-focused biotech Amarantus BioScience has entered into a clinical trial agreement with CRO Chiltern to manage the clinical research and monitoring program services for the Phase IIb study of eltoprazine in Parkinson’s disease levodopa-induced dyskinesia (PD-LID).
inVentiv Health has expanded its compliance products and services to assist biopharma companies conducting non-interventional studies (NIS).
In a House bill that largely mirrors one reintroduced earlier this year in the Senate, CROs (contract research organizations) would be able to capture a share of the R&D tax credit, thereby making the US more competitive with other countries that offer such credits.
Adaptive clinical trial designs can be used in medical device studies as long as they are for “prospectively planned modifications based on accumulating study data without undermining the trial’s integrity and validity,” the FDA says.
Our round-up of the latest hires and deals in outsourcing.